Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 2nd ranked industry out of 145 stock market industries

Ticker	Company	Price	Graham Fair Value	Graham Fair Value %	P/E	Forward P/E	P/S	P/B	PEG	Free Cash Flow	Free Cash Flow Yield	Book Value	BVPS	EV	EV/EBITDA
GRFS	GRIFOLS SA	$10.74	$12.30	-12.68%	41.95x	10.53x	0.92x	1.13x	0.36x	$357.52M	4.84%	$6.54B	9.51	$17.59B	10.28
NVS	NOVARTIS AG	$122.09	$74.13	64.69%	17.67x	13.56x	4.31x	5.63x	1.30x	$19.38B	8.15%	$41.99B	21.55	$262.34B	9.46
BIIB	BIOGEN INC	$134.94	$116.57	15.76%	12.88x	8.50x	1.98x	1.12x	0.88x	$1.83B	9.27%	$17.63B	120.37	$23.62B	9.06
LLY	ELI LILLY & CO	$684.43	$291.88	134.49%	44.59x	29.78x	11.54x	35.45x	1.23x	$4.88B	0.79%	$18.27B	20.35	$684.31B	36.49
AMRN	AMARIN CORP PLC	$15.04	N/A	N/A	-3.01x	-6.68x	1.42x	0.67x	N/A	-$11.52M	-3.70%	$464.92M	22.43	$170.23M	-1.80
AZN	ASTRAZENECA PLC	$78.47	$44.07	78.04%	29.33x	17.23x	4.31x	5.44x	1.00x	$11.19B	4.60%	$44.72B	14.43	$269.04B	14.53
GSK	GSK PLC	$39.23	$37.32	5.12%	17.28x	9.03x	1.86x	3.99x	0.59x	$8.76B	10.98%	$19.99B	9.84	$98.28B	13.15
GILD	GILEAD SCIENCES INC	$119.02	$69.73	70.68%	23.57x	14.67x	5.13x	7.51x	1.07x	$9.37B	6.32%	$19.67B	15.80	$167.48B	15.26
BMY	BRISTOL MYERS SQUIBB CO	$47.81	$43.89	8.94%	19.20x	7.33x	2.04x	5.58x	0.59x	$14.58B	14.98%	$17.44B	8.57	$133.90B	10.24
ABBV	ABBVIE INC	$204.68	$86.86	135.65%	97.00x	17.01x	6.20x	-1,975.84x	1.00x	$18.24B	5.04%	-$183.00M	-0.10	$425.59B	30.84
SNY	SANOFI	$49.04	$34.22	43.33%	11.30x	10.94x	2.37x	1.50x	1.95x	$11.50B	9.57%	$82.36B	33.60	$132.04B	7.31
JNJ	JOHNSON & JOHNSON	$174.72	$84.50	106.77%	18.57x	16.09x	4.64x	5.36x	2.11x	$18.55B	4.41%	$78.47B	32.61	$452.97B	12.71
PFE	PFIZER INC	$25.11	$23.14	8.53%	13.29x	8.06x	2.24x	1.61x	0.75x	$12.44B	8.71%	$88.70B	15.60	$202.92B	11.73
SCLX	SCILEX HOLDING CO	$17.37	N/A	N/A	-1.62x	-0.71x	4.55x	-0.49x	N/A	$20.70M	10.28%	-$248.99M	-21.47	$166.09M	-2.43
AMGN	AMGEN INC	$290.29	$169.46	71.30%	23.56x	13.77x	4.47x	21.04x	1.08x	$10.61B	6.79%	$7.43B	13.81	$204.46B	12.87
OGN	ORGANON & CO	$9.39	$33.26	-71.77%	3.46x	2.57x	0.39x	3.33x	0.19x	$662.00M	27.12%	$733.00M	2.82	$10.74B	7.17
MRK	MERCK & CO INC	$82.76	$78.26	5.76%	12.73x	9.25x	3.27x	4.22x	0.74x	$14.72B	7.09%	$48.99B	19.52	$234.11B	9.35
MIRA	MIRA PHARMACEUTICALS INC	$1.47	N/A	N/A	-2.88x	-3.34x	N/A	19.22x	N/A	-$6.14M	-25.10%	$1.29M	0.08	$23.67M	-2.95

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Aug 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #1 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 33, which is -11 points lower than the general drug manufacturer industry average of 44. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 13 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 54.02% over the past year, overperforming other general drug manufacturer stocks by 68 percentage points.

Grifols Sa has an average 1 year price target of $10.30, a downside of -4.1% from Grifols Sa's current stock price of $10.74.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Novartis Ag (NYSE:NVS)

Novartis Ag (NYSE:NVS) is the #2 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: B.

Novartis Ag (NYSE:NVS) has a Due Diligence Score of 39, which is -5 points lower than the general drug manufacturer industry average of 44. Although this number is below the industry average, our proven quant model rates NVS as a "A".

NVS passed 14 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 9.62% over the past year, overperforming other general drug manufacturer stocks by 24 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the #3 top general drug manufacturer stock out of 18 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Biogen (NASDAQ:BIIB) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: C.

Biogen (NASDAQ:BIIB) has a Due Diligence Score of 51, which is 7 points higher than the general drug manufacturer industry average of 44.

BIIB passed 15 out of 33 due diligence checks and has strong fundamentals. Biogen has seen its stock lose -31.26% over the past year, underperforming other general drug manufacturer stocks by -17 percentage points.

Biogen has an average 1 year price target of $173.92, an upside of 28.89% from Biogen's current stock price of $134.94.

Biogen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Biogen, 23.08% have issued a Strong Buy rating, 30.77% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 6.18%, which is 3 percentage points higher than the general drug manufacturer industry average of 2.91%.

Organon & Co's dividend payout ratio of 31.7% indicates that its high dividend yield is sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.51%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.91%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

3. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) has an annual dividend yield of 4.09%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.91%. Gsk's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 70.7% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 1.22% in the last day, and up 4.73% over the last week. Scilex Holding Co was the among the top gainers in the drug manufacturers - general industry, gaining 4.09% yesterday.

Scilex Holding shares are trading lower after the company reported worse-than-expected Q2 financial results.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 29 points higher than the general drug manufacturer industry average of 42. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -53.31% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -39 percentage points.

2. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 15 points higher than the general drug manufacturer industry average of 42. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -25.68% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -12 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 44 points higher than the general drug manufacturer industry average of 42. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -31.26% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -17 percentage points.

Are general drug manufacturer stocks a good buy now?

42.86% of general drug manufacturer stocks rated by analysts are a hold right now. On average, analysts expect general drug manufacturer stocks to rise by 52.31% over the next year.

11.11% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 55.56% of general drug manufacturer stocks are rated B (Buy), 27.78% are rated C (Hold), 5.56% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 35.06x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Grifols Sa (NASDAQ:GRFS)

2. Novartis Ag (NYSE:NVS)

3. Biogen (NASDAQ:BIIB)

1. Organon & Co (NYSE:OGN)

2. Sanofi (NASDAQ:SNY)

3. Gsk (NYSE:GSK)

1. Organon & Co (NYSE:OGN)

2. Merck & Co (NYSE:MRK)

3. Biogen (NASDAQ:BIIB)

Company

Stock Tools

Stock Ideas